Hepatocellular carcinoma is one of the most common
cancers and lethal diseases in the world. Recently, many researchers focused to identify novel chemotherapeutic agents from natural sources against hepatocarcinogenesis. The diverse therapeutic potential of
essential oils has drawn the attention of researchers to test them for anticancer activity, taking advantage of the fact that their mechanism of action is dissimilar to that of chemotherapeutic agents. Earlier reports indicated that
essential oil components, especially
monoterpenes, have multiple pharmacological effects which could account for the
terpene-
tumor suppressive activity. In the present study, it is shown that
myrtenal, a natural
monoterpene, which acts as an
antineoplastic agent against
diethylnitrosamine induced
phenobarbital promoted experimental
hepatocellular carcinoma. The results revealed an elevated level of microsomal lipid peroxidation in the liver, which was found to be significantly reduced by
myrtenal treatment. On the contrary, the Phase I hepatic
drug metabolizing
enzymes' (
cytochrome P(450),
cytochrome b(5),
NADPH-cytochrome c reductase,
NADH-
cytochrome b(5)
reductase) levels were decreased and the Phase II
enzymes (glutathione-S-transferase, uridine 5'-diphospho-glucuronyl transferase) were increased in
carcinogen-administered animals, which were reverted to near normalcy upon
myrtenal administration. Our findings also showed that
myrtenal restrains the
liver cancer by preventing the DEN-PB induced up-regulation of TNF-α
protein expression by immunoblot. Furthermore, transmission electron microscopic examination also indicated that
myrtenal prevents the
carcinogen-induced changes in the architecture of liver tissue and cell structure. Thus, this study shows that
myrtenal has the ability to suppress the
hepatocellular carcinoma in rats.